Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 23-31

  Sigaloff, Kim C E ^a   Hamers, Raph L ^a   Wallis, Carole L ^b   Kityo, Cissy ^c   Siwale, Margaret ^d   Ive, Prudence ^b   Botes, Mariette E ^e   Mandaliya, Kishor ^f   Wellington, Maureen ^g   Osibogun, Akin ^h   Stevens, Wendy S ^b   Van Vugt, Michèle ^a   Rinke De Wit, Tobias F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d Lusaka Trust Hospital   (Zambia)

^e Muelmed Hospital   (South Africa)

^f Department of Obstetrics and Gynaecology   (Kenya)

^g Newlands Clinic   (Zimbabwe)

^h LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

Africa; Drug resistance; Highly active antiretroviral therapy; HIV; Viremia copyright lippincott williams wilkins

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA; ANTIVIRAL RESISTANCE; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; CROSS RESISTANCE; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STANDARD; VIRUS LOAD; ADULT; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; TREATMENT FAILURE; VIROLOGY;

ADULT; AFRICA; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 80155174927     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318227fc34     Document Type: Article

References (39)

1. WHO. Towards Universal Access, Scaling up Priority HIV/AIDS Interventions in the Health Sector; Progress Report 2009. Geneva, Switzerland: World Health Organization; 2009.
2. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224. (Pubitemid 40962502)
3. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach; 2010 Revision. Geneva, Switzerland: World Health Organization; 2010.
4. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009;14:856-861.
5. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23:697-700.
6. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-1977.
7. Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;49:477-484.
8. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and metaanalysis. Lancet Infect Dis. 2009;9:409-417.
9. Hamers R, Oyomopito R, Kityo C, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV Drug Resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2011 [E-pub ahead of print].
10. Wallis CL, Papathanasopoulos MA, Lakhi S, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2009;163:505-508.
11. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20:355-364. (Pubitemid 38582265)
12. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
13. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21:3797-3800. (Pubitemid 41535530)
14. Gale CV, Myers R, Tedder RS, et al. Development of a novel human immunodeficiency virus type 1 subtyping tool, Subtype Analyzer (STAR): analysis of subtype distribution in London. AIDS Res Hum Retroviruses. 2004;20:457-464. (Pubitemid 38720958)
15. Steinberg DM, Fine J, Chappell R. Sample size for positive and negative predictive value in diagnostic research using case-control designs. Biostatistics. 2009;10:94-105. (Pubitemid 352847909)
16. Rewari BB, Bachani D, Rajasekaran S, et al. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. J Acquir Immune Defic Syndr. 2011 [Epub ahead of print].
17. Swanson P, de Mendoza C, Joshi Y, et al. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol. 2005;43:3860-3868. (Pubitemid 41129673)
18. Scott LE, Noble LD, Moloi J, et al. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009;47:2209-2217.
19. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49:1928-1935.
20. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS. 2002;16:1686-1689. (Pubitemid 34921117)
21. Turner D, Brenner BG, Routy JP, et al. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol. 2004;27(2 suppl 1):31-39. (Pubitemid 40090987)
22. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-1597. (Pubitemid 351706742)
23. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother. 2000;44:2109-2117. (Pubitemid 30484434)
24. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008;41:310-313.
25. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS. 2009;23:1127-1134.
26. Wallis CL, Mellors JW, Venter WD, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:480-484.
27. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009;14:523-531.
28. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9-F13. (Pubitemid 44030369)
29. Coutsinos D, Invernizzi CF, Xu H, et al. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother. 2010;20:117-131.
30. Kuritzkes DR, Bassett RL, Hazelwood JD, et al. Rate of thymidine analogue resistance mutation accumulation with zidovudine-or stavudinebased regimens. J Acquir Immune Defic Syndr. 2004;36:600-603. (Pubitemid 38544509)
31. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793. (Pubitemid 44223102)
32. Novitsky V, Wester CW, DeGruttola V, et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007;23:868-878. (Pubitemid 47267493)
33. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1449-1454.
34. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24:503-514.
35. Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010;24:1007-1012.
36. Fox MP, Ive P, Long L, et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:500-506.
37. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11:510-518.
38. Manosuthi W, Kiertiburanakul S, Amornnimit W, et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther. 2009;6:30.
39. Delaugerre C, Flandre P, Chaix ML, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother. 2009;53:2934-2939.